Drug intelligence / Profile preview

blood-derived induced pluripotent stem cells (Shandong Qilu Stem Cells Engineering)

Development stage: Preclinical
Lead developer: Shandong Qilu Stem Cell Engineering
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies

Overview

Blood-derived induced pluripotent stem cells (iPSCs) represent a research-stage cell therapy platform developed by Shandong Qilu Stem Cells Engineering (SINOCORD). The technology involves the reprogramming of adult cells obtained from peripheral blood into a pluripotent state, enabling them to potentially differentiate into various specialized cell types required for tissue repair and regeneration. This approach leverages the company's expertise in blood cell banking to provide a source for autologous or allogeneic regenerative therapies. The program is currently in the preclinical research phase, focusing on the generation and characterization of these cells for unspecified regenerative medicine applications.

Other names: blood-derived induced pluripotent stem cells-Shandong Qilu Stem Cells Engineering-cell therapy-iPSC-derived therapy-regenerative medicine (unspecified)blood-derived iPS cellsperipheral blood-derived induced pluripotent stem cells

Beyond the preview

Go deeper on blood-derived induced pluripotent stem cells (Shandong Qilu Stem Cells Engineering).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on blood-derived induced pluripotent stem cells (Shandong Qilu Stem Cells Engineering).

Explore the full profile